Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 4/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.62 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.62 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.62 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.62 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.62 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.62 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.62 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.62 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753744 | 0.85 | CA12 (0.50) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL17599105 | 0.84 | CYP1A1 (0.71) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL2850768 | 0.81 | KMT2A (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5917522 | 0.81 | SMN1; SMN2 (0.41) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL696471 | 0.81 | KCNH2 (0.45) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL5632975 | 0.81 | CYP1A1 (0.79) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL11523594 | 0.80 | CYP1A1 (0.51) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL2749830 | 0.80 | CYP1A1 (0.65) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL196689 | 0.80 | CYP1A1 (0.69) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 | |
| SCHEMBL29589241 | 0.80 | CYP1A1 (0.69) | CYP1A1CYP1B1CYP1A2CYP3A4CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362001-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | claimed |
| EP-2421848-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | claimed |
| WO-2010124119-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-6890930-B1 | Quinazolinones | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | claimed |
| US-8604017-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-10 | — | — | US | disclosed |
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-25 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8362001-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8178540-B2 | Pyrimidylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-05-15 | — | — | US | disclosed |
| US-5972959-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| CN-1219927-A | Phenylalkylcarboxylic acid derivatives | SANKYO CO (JP) | 1999-06-16 | — | — | CN | disclosed |
| EP-0916651-A1 | PHENYLALKYLCARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0708098-B1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1999-03-03 | — | — | EP | disclosed |
| US-5780490-A | A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS | SANKYO COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5703096-A | ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CYP1A1 523/4885CYP1B1 527/4885CYP1A2 544/4885 |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CYP1A1 523/4885CYP1B1 527/4885CYP1A2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.